A monoclonal antibody against IGF-1R (R1507) was able to restrict growth in osteosarcoma xenograft tumours alone and in the presence of the mTOR inhibitor rapamycin [254], but did not have a clinical effect in a phase II clinical trial [255]. This evidence concerns the gene MTOR and osteosarcoma.